ARTICLE | Emerging Company Profile
BrainChild: Bringing CAR Ts directly to the brain
Repeat dosing into the CSF is designed to sidestep the toxicities that have limited CNS-directed cell therapies
September 10, 2026 12:05 AM UTC
By delivering CAR T cells directly into the cerebrospinal fluid rather than the bloodstream, BrainChild says it can repeatedly dose CNS cell therapies without the systemic toxicities that have complicated other CAR T programs.
BrainChild Bio Inc., based in Seattle and Cambridge, Mass., announced Tuesday $116 million in series A financing backed by initial investor Seattle Children’s Research Institute and new investor WRF Capital. An undisclosed private family fund led the financing...